Nesina
Nesina contains alogliptin, an oral diabetes medicine that helps control blood sugar levels. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by increasing the levels of incretin hormones in the body, which stimulate the release of insulin after meals and decrease the amount of sugar made by the body.
Dosage by Body Weight
The standard recommended dose for adults is 25 mg taken orally once daily, with or without food. Dosage adjustments are required for patients with moderate to severe renal impairment or end-stage renal disease (ESRD).
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy of Nesina in pediatric patients under 18 years of age have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy of Nesina in pediatric patients under 18 years of age have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy of Nesina in pediatric patients under 18 years of age have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy of Nesina in pediatric patients under 18 years of age have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy of Nesina in pediatric patients under 18 years of age have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and efficacy of Nesina in pediatric patients under 18 years of age have not been established. |
| 5-7 kg | Not recommended | N/A | Safety and efficacy of Nesina in pediatric patients under 18 years of age have not been established. |
| 8-10 kg | Not recommended | N/A | Safety and efficacy of Nesina in pediatric patients under 18 years of age have not been established. |
| 11-15 kg | Not recommended | N/A | Safety and efficacy of Nesina in pediatric patients under 18 years of age have not been established. |
| 16-20 kg | Not recommended | N/A | Safety and efficacy of Nesina in pediatric patients under 18 years of age have not been established. |
Formulation
Purpose
Used to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
Generic Name
AlogliptinScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.